Sexual side effects are common on antidepressants, and the rate differs substantially between drugs. A meta-analysis comparing them found agomelatine, bupropion and mirtazapine produced rates close to placebo, while the SSRIs sat considerably higher. [serretti-2009-sexual] That difference is the part worth taking to an appointment, because it turns an apparently unavoidable cost of treatment into a question about which drug.
Why the between-drug difference is the useful finding
Because it changes what the problem is. If every antidepressant carried the same effect, the only question would be whether treatment is worth the cost, which is a bleak choice to be handed. Since the rates differ by drug, the question becomes which one, and that is a question with an answer.
The mechanism follows the same logic. Drugs that raise serotonin availability broadly are the ones most associated with delayed orgasm and reduced desire, while drugs working through other systems produce much less of it. [serretti-2009-sexual] That is why a switch is a genuine option rather than a hope, and why “antidepressants do this” is too coarse a statement to be worth acting on.
A schematic of the pattern described by Serretti and Chiesa. Drawn to show the shape of the difference between drug groups rather than reproducing reported percentages.
What actually gets affected
Desire and orgasm more than arousal, and delayed or absent orgasm is the effect most consistently described with SSRIs. A pooled analysis of randomised trials put orgasmic difficulty at roughly three times the rate seen on placebo.
Which part is affected is worth naming precisely at an appointment rather than reporting as a general loss of interest, because the adjustments differ. Difficulty reaching orgasm, loss of desire with function otherwise intact, and reduced physical arousal are three different reports, and a doctor hearing “my sex drive has gone” cannot tell which one is in front of them.
The response that causes the most harm
Stopping without saying anything. It is by a distance the commonest thing that happens, and it converts a manageable side effect into a relapse.
The reasoning behind it is understandable: the side effect is embarrassing to raise, appointments are short, and the medication feels like the obvious thing to remove. What that reasoning misses is that the alternative is not “put up with it”. Dose changes, timing changes, adding something, and switching to a drug with lower rates are all ordinary clinical moves, and none of them is available to somebody who has already stopped and not said why.
Is this worth raising at your next appointment?
For anyone on an antidepressant who has noticed a change and has not mentioned it.
0 of 6 ticked
The last item is the one that matters most here. Stopping without telling the prescriber removes every option they have, and the evidence on between-drug differences is the reason a switch is a real conversation to have.
This is the pattern where an adjustment usually exists. Say which part changed and when it started, rather than describing it in general terms, because that is what points at the adjustment.
Few of these suggests something other than the medication may be driving it, which is worth knowing since low mood itself affects desire and the two are easy to confuse.
Take the depression self-assessment
A reflection prompt rather than a screener. The linked PHQ-9 measures depressive symptoms and says nothing about medication side effects, so it speaks to the other half of the picture.
Symptoms that persist after stopping
Reported, reviewed, and not yet quantifiable. A 2023 systematic review of persistent sexual dysfunction after SSRI treatment found the available studies too few and too varied in method to produce a reliable estimate of how often it occurs. [tarchi-2023-pssd]
That conclusion is worth reading precisely, because it is routinely rounded in both directions. It does not say the phenomenon is not real, and it does not supply a risk figure. Anybody quoting a percentage for this is quoting something the evidence does not currently support, and the honest position is that it is a recognised concern with an unknown frequency. It is a reasonable thing to ask a doctor about before starting; it is not a reason to stop something that is working.
What to say at the appointment
Name the part, the timing and the direction. “Reaching orgasm takes much longer since the dose went up” gives a prescriber something to work with; “my sex drive is bad” does not, and it is also true of untreated depression, which is precisely the ambiguity that needs resolving.
Then ask the two questions that open the options: whether a dose or timing change is worth trying, and whether one of the drugs with lower rates would suit your situation. Both are ordinary requests. Neither implies you want to stop treatment, which is often the fear that keeps the subject closed.
When to seek help
Speak to a doctor if a sexual side effect is affecting your relationship, your mood or your willingness to keep taking a medication that is otherwise helping, and raise it before you change anything yourself. Do not stop an antidepressant abruptly. If your mood is worsening, treat that as the more urgent item in the same conversation, and if you are having thoughts of harming yourself, contact your local emergency services or a crisis helpline.
How MyFreud can help
Tracking helps here for a reason specific to this problem: the question a prescriber cannot answer from one conversation is whether the change followed the medication or the depression, and a record that shows what shifted and when settles it. Our sexual dysfunction guide covers the wider picture, and the depression self-assessment measures the mood side.
Download MyFreud and start today: App Store or Google Play.